Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsDowngradesPrice Target
Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.
Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.